A dedicated study involving exclusively RAS/BRAF wild-type patients would be necessary to establish whether anti-EGFR therapy is superior to anti-VEGF therapy in terms of inducing tumor fibrosis ≥40%. The gene discussed is BRAF; the disease is neoplasm.